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402-7 Use of Selective Serotonin Reuptake Inhibitors After 
Coronary Stent Implantation Reduces Adverse 
Cardiovascular Events
Kevin J. Woolf, Esther S. Shao, Stephen Sidney, Michael Sorel, Charles P. Quesenberry, 
Jr., Robert J. Lundstrom, Kaiser Permanente Northern California, San Francisco, CA
Background: Depression is a major risk factor for cardiovascular (CV) disease and 
predicts adverse outcomes. Data suggests selective serotonin reuptake inhibitors (SSRIs) 
are protective in CV disease. SSRIs deplete platelet serotonin and inhibit aggregation. 
Thrombosis, restenosis and progression of atherosclerosis involve platelet function. We 
hypothesized that SSRI use might reduce adverse CV events after stent placement.
Methods: Employing electronic databases we retrospectively identified 10,410 bare 
metal coronary stent recipients during a seven year period with at least two years of 
follow up. Patients were classified into three groups based on medications given: SSRIs, 
tricyclic antidepressants, or no antidepressants. Relative hazards for the endpoints of CV 
death, myocardial infarction (MI), and repeat revascularization were estimated using Cox 
proportional hazards regression models.
Results: Of the 8,893 patients included in the analysis, 7,475 were on no antidepressant, 
981 were on SSRIs, and 506 were on tricyclics. Compared with no treatment, SSRI 
treated patients had a significantly lower combined two year endpoint of CV death, MI, or 
repeat revascularization (hazard ratio [HR] 0.63, 95% confidence intervals [CI] 0.48-0.81, 
p=0.0005) and the individual endpoints of MI (HR 0.43, 95% CI 0.27-0.68, p=0.0003) and 
repeat revascularization (HR 0.76, 95% CI 0.58-0.98, p=0.04). Rate of CV death was 
similar (HR 0.83, 95% CI 0.34-2.03, p=0.7). As expected, a diagnosis of depression was 
associated with significantly increased risk for the combined endpoint (HR 1.16, 95% CI 
1.05-1.28, p=0.004) and the individual endpoint of MI (HR 1.34, 95% CI 1.17 to 1.55, 
p<0.0001), but did not affect risk of repeat revascularization (HR 1.10, 95% CI 0.99-1.23, 
p=0.09) or CV death (HR 0.64, 95% CI 0.40-1.02, p=0.06). There were no differences 
between the tricyclic group and the no antidepressant group.
Conclusions: SSRI use after bare metal coronary stenting is associated with a significant 
decrease in MI and repeat revascularization despite an increased rate of adverse events 
in patients with depression. This benefit likely results from effects of SSRIs on serotonin 
levels and platelet aggregation.
9:45 a.m.
402-8 Sport-Specific Changes in Cardiac Structure and 
Function:
A Prospective and Longitudinal Assessment of Competitive Athletes
Aaron L. Baggish, Francis Wang, Rory B. Weiner, Jason M. Elinoff, Francois Tournoux, 
Arthur Boland, Michael H. Picard, Adolph M. Hutter, Jr., Malissa J. Wood, Massachusetts 
General Hospital, Boston, MA
Background: Though numerous cross-sectional studies have identified an association 
between athletic participation and abnormal cardiac morphology, longitudinal studies 
examining this issue are lacking. We sought to define and quantify changes in cardiac 
structure and function that occur during participation in two disciplines of competitive 
athletics.
Methods: Competitive endurance athletes (EA) and strength athletes (SA) were studied 
with echocardiography at baseline and after three-months of team training.
Results: Sixty-four athletes completed the training period. Training volume was similar 
in both groups (EA= 11.6 ± 2.3 hrs/ week vs. SA= 13.3 ± 3.2 hrs/week; p=NS). Left 
ventricular (LV) mass increased by 11% in EA (116 ± 18 g/m2 vs. 130 ± 19 g/m2; p 
<0.001) and by 12% in SA (115 ± 14 g/m2 vs. 132 ± 11 g/m2; p <0.001). LV hypertrophy 
in EA was accompanied by LV dilation (LV end-diastolic volume: 66.6 ± 10.0 ml/m2 vs. 
74.7 ± 9.8 ml/m2, Δ = 8.0 ± 4.2 ml/m2; p<0.001), enhanced LV diastolic function (E1 
Basal Lateral LV: 10.9 ± 0.8 cm/s vs. 12.4 ± 0.9 cm/s, p<0.001), and biatrial enlargement 
while the LV hypertrophy in SA was characterized by wall thickness increase (posterior 
LV wall: 4.5 ± 0.5 cm/m2 vs. 5.2 ± 0.5 cm/m2, p<0.001) and diminished diastolic function 
(E1 Basal Lateral LV: 11.6 ± 1.3 cm/s vs. 10.2 ± 1.4 cm/s, p<0.001). EA experienced right 
ventricular (RV) dilation (RV end-diastolic area: 1460 ± 220 mm/ m2 vs. 1650 ± 200 mm/
m2, p< 0.001) coupled with enhanced systolic and diastolic function (E1 Basal RV: 10.3 
± 1.5 cm/s vs. 11.4 ± 1.7 cm/s, p<0.001) while SA had no change in RV parameters. All 
cardiac responses to endurance training were similar among males and females.
Conclusions: Participation in competitive team athletics produces significant changes 
in cardiac structure and function. Specifically, endurance athletes develop biventricular 
dilation with enhanced diastolic function while strength athletes develop isolated, 
concentric left ventricular hypertrophy with diminished diastolic relaxation. Further study 
is warranted to determine the long term significance of these observations.
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402-5 Mutant Atrial Natriuretic Peptide: Enhanced cGMP 
Activating, Natriuretic and Renin-Angiotensin-
Aldosterone Inhibiting Actions
Paul M. McKie, Alessandro Cataliotti, Brenda K. Huntley, Fernando L. Martin, Timothy M. 
Olson, John C. Burnett, Jr., Mayo Clinic, Rochester, MN
Background: The cardiac hormone atrial natriuretic peptide (ANP) is a 28 amino acid 
(AA) peptide which consists of a 17 AA ring structure together with a 6 AA N-terminus and 
a 5 AA C-terminus. In a targeted scan for sequence variants within the human ANP gene, 
a mutation was identified which results in a 40 AA peptide consisting of native ANP(1-28) 
and a C-terminal extension of 12 AA. We have termed this peptide mutant ANP (m-ANP) 
and sought to determine its cardiorenal physiologic actions. We hypothesized that m-ANP 
would be capable of activating 3’,5’-cyclic guanosine monophosphate (cGMP), the second 
messenger of ANP, in vitro. Secondly, we hypothesized that the extended C-terminus of 
m-ANP would result in more sustained biological actions compared to native ANP.
Methods: In vitro cGMP activating properties of m-ANP were assessed in cultured 
human cardiac fibroblasts, which express all the natriuretic peptide receptors. In vivo 
studies were performed in normal dogs.
Results: We observed an incremental in vitro cGMP dose response with increasing 
concentrations of m-ANP in cultured human cardiac fibroblasts. With high dose m-ANP 
(33 pmol/kg/min) , in vivo (n=7),
 
we observed significantly greater diuretic, natriuretic, 
glomerular filtration rate enhancing, renin-angiotensin-aldosterone system inhibiting, 
cardiac unloading and blood pressure lowering properties when compared to native ANP 
(n=7). These actions were sustained up to 120 minutes post infusion. The enhanced 
cardiorenal and neurohumoral properties observed with m-ANP were associated with 
a significantly greater increase in plasma cGMP than with native peptide. We further 
observed that low dose m-ANP
 
(2 pmol/kg/min) (n=7) has natriuretic and diuretic 
properties without altering systemic hemodynamics compared to no natriuretic or diuretic 
response with low dose native ANP (n=7).
Conclusions: These studies establish that m-ANP activates cGMP in cultured human 
cardiac fibroblasts and exerts greater and more sustained natriuretic, diuretic, glomerular 
filtration rate, and renal blood flow enhancing actions than native ANP. These results 
suggest m-ANP may serve as a novel saluretic and diuretic agent in sodium retaining 
syndromes.
9:15 a.m.
402-6 Obesity Increases Vascular Senescence and 
Susceptibility to Ischemic Injury Through Chronic 
Activation of Akt/mTOR
Chao-Yung Wang, James K. Liao, Brigham and Women’s Hospital, Boston, MA
Background: Obesity and age are important risk factors for cardiovascular disease. 
However, the pathophysiological mechanism linking obesity with age-related diseases 
has not been established. While the life-shortening effects of many chronic diseases 
associated with obesity are evident, the direct link between obesity itself and decreased 
life span is poorly understood. We hypothesize that obesity increases vascular 
senescence and susceptibility to age-related diseases, such as stroke, through chronic 
activation of Akt/mTOR and vascular senescence could be prevented by inhibition of Akt/
mTOR signaling.
Methods and Results: Here we show that induction of obesity in mice with a high fat diet 
increases vascular senescence by mechanisms involving chronic repetitively activation of 
protein kinase Akt and mammalian target of rapamycin (mTOR). Mutant mice with chronic 
Akt/mTOR activation exhibit vascular senescence and are more prone to peripheral and 
cerebral ischemia. Obese mice caused by high fat diet and mutant mice with chronic Akt/
mTOR activation both have 45% and 40% worsened responses to peripheral ischemia, 
respectively. Rapamycin decreases phosphorylation of Akt at the dosage of 0.2mg/kg/
day and at the duration of one week. Treatment of diet-induced obese mice or mutant 
mice with chronic Akt activation with rapamycin prevents vascular senescence without 
altering body weight. Rapamycin also reduces the severity of limb necrosis and ischemic 
stroke size associated with vascular dysfunction by 50% and 60%, respectively. Akt1 null 
mice also showed resistance to vascular senescence phenotype associated with diet 
induced obesity. While they have similar degree of insulin resistance, endothelial cells 
from Akt1 null mice showed less replicative senescence and have 60% less of replicative 
senescence induced by obesity.
Conclusion: These findings indicate that diet-induced obesity can enhance 
cardiovascular risks by increasing vascular senescence and decrease vascular function. 
Modulation of Akt/mTOR signaling may have therapeutic benefits in preventing age-
related cardiovascular disease in obese individuals.





402-9 Association of Adventitial Neovascularization with 
Plaque Remodeling and Composition in a Porcine 
Model of Complex Coronary Atherosclerosis: 
Implications for the Validation of Imaging and 
Therapeutic Interventions
Carlos L. Alviar, Armando Tellez, Angela Builes, Gabriel Lopez-Berestein, Angela 
Sanguino, David Wallace-Bradley, Christie M. Ballantyne, Chao-Yuh Yang, Eli I. Lev, Neal 
S. Kleiman, Grzegorz L. Kaluza, Juan F. Granada, The Methodist Hospital Research 
Institute, Houston, TX, Cardiovascular Research Foundation, New York, NY
Background: In human atherosclerosis, neovascularization is associated with lesion 
complexity, inflammation and remodeling. Accordingly, we sought wheter the degree of 
neovascularization in our pig model of localized atherosclerotic coronary lesions in 12 
weeks is similarly related to plaque composition and remodeling.
Methods: Injection of a previously described lipid mixture was performed in 30 coronary 
segments of 5 pigs fed a high cholesterol diet for 12 weeks. Lesions were evaluated 
by IVUS, histology and immunohistochemistry, and stratified into 3 tertiles according to 
neovessel density.
Results: We analyzed 57 lesions; fatty streaks were found in 8.7% cases, pre-atheromas 
in 54.5% and thick cap fibro-atheromas in 36.8%. The neovessel were counted and 
normalized per plaque area. The neovessels density per visual field was proportional 
to the degree of plaque burden (15.6 ± 7.2 in plaques with 60% stenosis, P<0.01) and 
to macrophage density (123.4±146.2, 60% stenosis, p<0.05). Lesion collagen content 
was linked to neovessel density (32.4±14.1%, lower tertile of neovessel density vs. 
47.5±8.9%, upper tertile of neovessel density, p< 0.01) while smooth muscle cell content 
was inversely related (49.7%±18.9% vs. 36.4%±14.4%, p<0.05). Highly neovascularized 
plaques more frequently featured positive remodeling (mean remodeling index in lower 
tertile 0.89±0.32 vs. 1.36±0.73 in upper tertile, p<0.05) and more abundant macrophage 
infiltration (161.42±157.6 in lower tertile vs. 340.6±127.2 in upper tertile, p<0.05).
Conclusion: In our porcine model of coronary lesions induced by intramural lipid 
injections, the degree of adventitial neovascularization appears to be related to the 
hallmarks of lesion maturity. Despite its temporally accelerated character, the model 
appears to produce pathophysiologic features resembling those seen in human 
atherosclerosis. This model might be useful as a future tool for diagnostic and therapeutic 
technology development in interventional cardiology
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405-5 Off-label Use of Cardiovascular Medications in Children 
Hospitalized with Congenital and Acquired Heart 
Disease
Sara K. Pasquali, Matthew Hall, Anthony D. Slonim, Kathy J. Jenkins, Bradley S. Marino, 
Meryl S. Cohen, Samir S. Shah, The Children’s Hospital of Philadelphia, Philadelphia, PA
Background: Many barriers exist to conducting pediatric cardiovascular (CV) trials, and 
the majority of therapies used in this population are not evidence-based. Recent federal 
legislation has aimed to stimulate pediatric research and improve drug labeling. The 
purpose of this study was to describe current off-label use of CV medications in children 
hospitalized with congenital and acquired heart disease.
Methods: The Pediatric Health Information System database from 34 US tertiary care 
pediatric hospitals was utilized. Patients discharged in 2005 with ICD-9 codes for CV 
disease, and CV medications used in >0.1% were included. Off-label use was defined as 
use of a drug in a patient younger than the Food and Drug Administration (FDA) approved 
age. Multivariate analysis was performed using Poisson regression to model the number 
of CV drugs received off-label.
Results: There were 43,182 patients included [median age 10m (interquartile range 
30d-7y), 55% male]. Diagnoses included: congenital heart disease (40% medical, 27% 
procedural), hypertension (15%), arrhythmia (13%), myocarditis/cardiomyopathy (2%), 
pulmonary hypertension (2%), and rheumatic fever/endocarditis and heart transplant 
(both <1%). 78% received ≥1 drug off-label, and 31% received ≥ 3 drugs off-label. The 5 
most commonly used CV drugs were furosemide, epinephrine, dopamine, lidocaine, and 
milrinone. The latter 3 (prescribed in 69%) were used off-label in all cases. CV medications 
studied under recent federal initiatives were prescribed in only 20% of patients, and were 
still used off-label 62% of the time. In multivariate analysis, heart transplant recipients (OR 
5.0, 95%CI 4.3-5.9) and patients undergoing congenital heart surgery (OR 2.8, 95%CI 
2.6-3.1) were most likely to receive a greater number of off-label CV medications.
Conclusions: Despite recent legislation, off-label use of CV medications is common, 
particularly in those undergoing heart transplant and congenital heart surgery. This data 
highlights the significant need for further study to determine which treatments should be 
used more frequently, and which are unsafe or ineffective in children hospitalized with 
CV disease.
2:45 p.m.
405-6 Quantitative ECG Analysis Improves Management of 
Atrial Tachyarrhythmias Compared to Experts
David E. Krummen, Mitul Patel, Hong Nguyen, Gordon Ho, Dhruv Kazi, Paul Clopton, 
Scott Greenberg, Gregory K. Feld, Mitch Faddis, Sanjiv M. Narayan, University of 
California San Diego, San Diego, CA, VA San Diego Healthcare System, San Diego, CA
Background: Errors in surface ECG interpretation by clinicians at all levels of training 
and their sequelae are being increasingly recognized. We hypothesized that quantitative 
analysis of the surface ECG in patients with atrial tachyarrhythmias would significantly 
improve upon the diagnostic accuracy of experts and would improve healthcare resource 
utilization.
Methods: We performed a prospective, blinded, multicenter trial to test our hypotheses, 
using analysis by a validated computerized algorithm to identify typical atrial flutter (TAFL), 
atypical atrial flutter (AAFL), atrial tachycardia (AT) and atrial fibrillation (AF) from the 
ECG, in patients referred to electrophysiology study (EPS). ECGs were also interpreted 
by each of 3 blinded panels of trained clinicians of graded levels of experience. Diagnostic 
accuracy was compared to the gold standard of invasive EPS simultaneous with each 
ECG. Decision analytic modeling was used to estimate the clinical and economic impact 
of the use of quantitative ECG analysis.
Results: A total of 122 consecutive patients referred to EPS were enrolled in the 
study, in whom 91 atrial tachyarrhythmias were observed in 89 patients (age 60±12 
years). The diagnostic accuracy of board certified internists, general cardiologists and 
electrophysiologists were 46+12%, 62+12% and 59+13%, respectively. Quantitative 
diagnosis was correct in 76% of cases, improving upon diagnosis by the panels of 
internists (p<0.05), cardiologists, and electrophysiologists (p<0.05). In a Markov model 
for a hypothetical cohort of 1,000 65-year old patients with atrial tachyarrhythmias, a 
cost-savings of $656,160 and a marginal but consistent improvement in the quality of life 
(0.005 QALYs) was demonstrated at 5 years.
Conclusions: Quantitative diagnosis of atrial arrhythmias improves quality and cost-
effectiveness of patient care.
3:00 p.m.
405-7 Influence of Body Mass Index on Revascularization 
Decisions and Outcomes in Patients with Coronary 
Artery Disease: a 15-Year Experience From the Duke 
Databank
Aslan T. Turer, Kenneth W. Mahaffey, Emily Honeycutt, Robert H. Tuttle, Linda K. Shaw, 
Michael H. Sketch, Peter K. Smith, Robert M. Califf, John H. Alexander, Duke University 
Medical Center, Durham, NC
Background: BMI is associated with overall and cardiovascular mortality. The association 
between BMI and survival with coronary artery disease (CAD) after accounting for 
differences in therapy has not been established.
Methods: Using the Duke Database for Cardiovascular Disease, we selected 22,877 
patients who underwent cardiac catheterization from 1986-2004 and were found to have 
significant CAD. Patients were categorized into three CAD management groups based 
on an adopted therapeutic strategy: medical therapy (MED), percutaneous coronary 
intervention (PCI) and bypass surgery (CABG). Relationships between BMI, CAD 
treatment and survival were assessed via Cox modeling. Propensity scoring was used to 
control for non-randomized CAD treatment assignment in the final model.
Results: Short-term (30-day) survival did not differ across BMI among the three 
treatment groups, but the survival curves separated over the intermediate- and long-
term. An “inverted U-shaped” survival function was noted across all time points after 30 
days, with the lowest risk of death at a BMI of approximately 26 kg/m2 which was seen 
independent of treatment assignment. CABG appeared to be associated with the highest 
survival at all later timepoints, while MED management was associated with the lowest. 
BMI was a significant, albeit relatively weak, predictor of undergoing revascularization. 
Higher BMI predicted lower rates of CABG use in propensity for treatment modeling, a 
finding supported by a trend towards lower CABG use for 3 vessel or left main disease 
among severely obese patients (BMI≥40) compared with those with BMI<40 (55.3% vs 
61.5%, p=0.072).
Conclusions: Extremes of BMI are associated with lower survival after the diagnosis 
of CAD, with the nadir of risk at a BMI of approximately 26kg/m2. Revascularization is 
associated with greater survival over the intermediate-term while CABG is associated 
with the highest long-term survival. These trends hold across the BMI spectrum 
suggesting similar benefit despite extremes of weight. Despite this, there may be a bias 
against revascularization with CABG in the very obese patient. With the growing obesity 
epidemic, these results have clear implications.
3:15 p.m.
405-8 Survival Benefits and Dose-Response Effect of Cardiac 
Rehabilitation in Medicare Beneficiaries after a Cardiac 
Event or Revascularization
Jose Suaya, Schneider Institutes for Health Policy, Waltham, MA
Background: Randomized control trails and meta-analyses have shown that the use 
of cardiac rehabilitation (CR) improves survival. However, most participants in these 
trials were middle-aged, predominantly low or moderate risk, white men. We assessed 
the survival benefit of CR in a national cohort of 601,099 elderly Medicare beneficiaries 
hospitalized for a coronary condition or cardiac revascularization procedure in 1997.
Methods: We first used propensity-based matching to compare five-year survival 
in 70,040 paired CR-users and non-users, stratified by 12 coronary groups. Next, we 















examined dose-response relationships by propensity-based matching of 17,298 paired 
lower-dose (< 25 sessions) to higher-dose CR-users. Finally, we compared five-year 
survival of CR-users and non-users in the entire cohort using two validated instrumental 
variables.
Results: CR-users, representing 12.2% of the cohort, averaged 24 CR sessions. All 
matched pairs were well-balanced on all observable variables. Five-year cumulative 
mortality rates were 16.3% in CR-users and 24.6% in matched non-CR-users, a 34% 
relative reduction (p<0.0001). Significant mortality reductions were observed in all 
coronary groups with the greatest improvement in the highest risk group, patients with 
heart attack, congestive heart failure, and no revascularization. High-CR-users had a 
five-year cumulative mortality of 14.0% compared to 17.2% in low-users (p< 0.0001). 
The five-year mortality reduction from CR use using instrumental variables was 74.2% 
of that from propensity-based matching (p < 0.05). Both methods found significant but 
diminishing mortality reductions from CR in each year.
Conclusions: The observed survival benefits of CR use in this unselected 
socioeconomically and clinically diverse elderly population under routine care were 
similar to those observed in published randomized-control trials and meta-analyses in 
younger populations.
3:30 p.m.
405-9 Heart Failure Patients Have Drops in Intrathoracic 
Impedance Preceding Ventricular Fibrillation Episodes
Matthew N. Peters, Hans Moore, Pamela Karasik, Michael Franz, Wassim Choucair, 
Steven Singh, Ross Fletcher, Washington Veterans Affairs Medical Center, Washington, 
DC, University of Maryland School of Medicine, Baltimore, MD
Background: Heart failure (HF) is associated with ventricular fibrillation (VF), possibly 
from increased myocardial stretch. Intrathoracic impedance (TI) is correlated with left 
ventricular filling pressure. Implanted defibrillators (ICD’s) capable of daily calculations 
of TI can correlate changes in TI with VF. We hypothesized that VF is preceded by drops 
in TI in HF patients.
Methods: Data from remote ICD follow-up was retrospectively analyzed. All patients with 
ICD’s capable of trending TI (Medtronic Optivol) were reviewed for VF zone episodes. 
TI values were obtained on the date of VF episode (D0), the day before (D1), two days 
before (D2), and seven days (D7) before D0.
Results: A subset consisting of 317 VF episodes among 1570 patients’ remote follow-up 
data were evaluable in a cohort of 121 HF patients. A drop in TI was observed > 50% of the 
time. When the TI on D7 was compared to the TI on D0, 52% of episodes were preceded 
by at least a 5% drop in TI. TI Drop was calculated as the summation of the differences 
between observed and reference TI on D7, D2, and D1. TI Drop more negative than zero 
was found in 66% of VF (p<0.001). In 50% of VF the TI Drop was more negative than -3. A 
TI Drop more negative than -4 is significantly less than random (P<0.01).
Conclusions: 1) In HF patients 67% of VF episodes are preceded by TI Drop; 2) Myocardial 
stretch might cause VF episodes in HF patients; 3) VF episodes might be predicted 
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406-5 Reporter Gene Imaging for Survival Monitoring of 
Transplanted Endothelial Progenitor Cells in the Rat 
Heart after Pretreatment with VEGF and Atorvastatin
Takahiro Higuchi, Martina Anton, Antti Saraste, Katja Ahrens, Jaroslav Pelisek, Stephan 
G. Nekolla, Frank M. Bengel, Rene M. Botnar, Markus Schwaiger, Nuklearmedizinische 
Klinik und Poliklinik der Technischen UniversitÃ¤t MÃ¼nchen, Munchen, Germany
Background: VEGF and statins have been suggested to enhance survival of endothelial 
progenitor cells (EPCs). We investigated whether reporter gene imaging by PET can be 
used to monitor effects of atorvastatin and VEGF on survival of transplanted EPCs in 
the heart.
Methods: Nude rats received a intramyocardial injection of 4 million human EPCs 
transduced with the sodium/iodide symporter (NIS) gene for reporter gene imaging. 
Reporter gene expression was imaged at day 1 and 3 after injection in a small animal 
PET scanner with I-124 and presence of EPCs was confirmed by immunohistochemistry 
with human CD31 antibodies. Control group (n=5) received EPCs only transduced with 
the reporter gene. Pretreatment group (n=5) received oral atorvastatin (10mg/kg/day) and 
EPCs that were transduced with both VEGF and the reporter gene.
Results: Immunohistochemistry showed more graft EPCs at the site of injection in the 
pretreatment group than in controls. PET imaging successfully visualized graft EPCs as 
focal I-124 accumulation at the site of injection. The amount of accumulation (percentage 
of injected dose) was significantly higher in the pretreatment than in the control group 
(0.097 vs. 0.058 on day1 and 0.059 vs. 0.037 on day3).
Conclusions: Early survival of transplanted EPCs in the rat myocardium is prolonged 
by pretreatment with a combination of atorvastatin and VEGF. Reporter gene PET 
imaging has been shown to successfully quantify this effect making it an attractive tool for 
monitoring of stem cell survival in-vivo. 
4:15 p.m.
406-6 Senescent vascular smooth muscle cells play an 
important role in the formation of vascular calcification
Ritsuko Nakano, Koji Ikeda, Maki Uraoka, Yusuke Nakagawa, Kotaro Yutaka, Hiroaki 
Matsubara, Kyoto Prefectural Unversity of Medicine, Kyoto, Japan
Background: Medial artery calcification proceeds in elderly people and contributes 
to vascular stiffness, leading increased pulse-wave velocity, decreased diastolic and 
increased systolic blood pressure. Thus medial artery calcification is highly associated 
with mortality in elderly people. Lately, various factors associated with bone-mineralization 
have been reported to play particular roles in the vascular calcification. Methods and 
Results: Aged cells were generated by long-term culture of primary human coronary 
artery smooth muscle cell (HCASMC) and umbilical vein endothelial cell (HUVEC). 
Cellular senescence was confirmed by senescence-associated β-galactosidase activity 
as well as by expression of p21. We analyzed gene expression associated with bone-
mineralization in aged cells (passage (P)22HUVEC and P13HCASMC), and compared 
it to young cells (P5HUVEC and P6HCASMC). BMP-2, an initiator for osteoblast 
differentiation was significantly up-regulated in aged HCASMC whereas MGP, a potent 
inhibitor of calcification was down-regulated. These alterations of gene expression were not 
observed in aged HUVEC. Moreover, expression of osteoblast markers such as alkaline 
phosphatase (ALP), type-I collagen and RUNX-2 was significantly up-regulated in aged 
HCASMC. Calcification of aged HCASMC was dramatically enhanced as compared to 
young cells. Notably, this enhanced calcification was inhibited by the treatment with ALP 
inhibitor, indicating that enhanced ALP activity is involved in the increased calcification 
of aged HCASMC. In addition, fluvastatin also inhibited VSMC calcification presumably 
through increasing MGP expression. Furthermore, immunohistochemistry of aorta from 
aging model mouse, klotho-/- mouse demonstrated that βSMA+ VSMC in the media 
expressed an osteoblast marker, RUNX-2 only in the region where initial calcification was 
observed. Conclusion: We identified the potential role of aged VSMC in the formation of 
vascular calcification associated with aging through the transformation into osteoblast-like 
cells. Our data define the significant molecular link between vascular calcification and 
VSMC senescence.
4:30 p.m.
406-7 Atherosclerosis Regression Promoted by an LXR 
Agonist is Dependent on the Chemokine Receptor 
CCR7 and Requires Both LXRα and LXRα
Jonathan E. Feig, Ines Pineda-Torra, Michael J. Garabedian, Edward A. Fisher, New 
York University School of Medicine, New York, NY
Background: By understanding the factors that lead to atherosclerosis regression, better 
treatment options may be developed for many who already carry a heavy plaque burden. 
We reported a mouse model of atherosclerosis regression that involves transplanting 
an atherosclerotic aortic arch into a normolipidemic mouse. There, emigration of plaque 
foam cells occurred in a CCR7 (dendritic cell migration factor) dependent manner. 
Concurrent increases in LXR, a transcription factor that mediates lipid homeostasis, was 
also observed. In this study, we examined the relatedness of these two factors.
Methods: We used siRNA, chromatin immunoprecipitation (ChIP), chemotaxis, and in 
vivo transplantation approaches.
Results: In an immature dendritic cell line (D2.4), we found that CCR7 levels increased 8X 
upon LXR activation by the agonist T0901317. Using ChIP, we show that LXR is recruited 
to the CCR7 promoter. When siRNA to LXRβ and LXRβ was used and then LXR agonist 
administered to D2.4 cells, CCR7 expression was blunted to 2X. To extend the results in 
vivo, we treated western-diet fed apoE-/- mice with LXR agonist. Interestingly, CCR7 was 
induced in foam cells and foam cell content as well as lesion area decreased by 21% and 
24%, respectively. When we treated apoE-/-CCR7-/- mice with LXR agonist, foam cell 




content was only decreased by 9% suggesting that CCR7 mediates foam cell depletion. 
To address whether LXR is required for regression, we used apoE-/-, LXRβ-/-apoE-/-, 
and LXRβ-/-apoE-/- mice as donors and wild types as recipients. Transplanted plaques 
from either of the double knockouts (DKOs) exhibited impaired regression as foam cell 
content and lesion area only decreased by 35% and 28%, respectively instead of 67% 
and 59% in lesions that originated from apoE-/- mice. In addition, CCR7 expression in 
foam cells from transplanted DKO lesions were 38% lower compared to levels in foam 
cells from transplanted apoE-/- plaques suggesting that both LXR isoforms are essential 
for CCR7 expression.
Conclusion: LXR activation promotes regression of atherosclerotic lesions in a CCR7 
dependent manner. Our results suggest macrophage LXRβ, LXRβ, and CCR7 as potential 
targets for the treatment of atherosclerosis.
4:45 p.m.
406-8 Cardiac resident stem cells exhibit mesenchymal 
features and provide no long term benefit to cardiac 
function in mouse ischemic model of heart failure
Zongjin Li, Hyung Chun, Xiaoyan Xie, Mei Huang, Grant Hoyt, Pauline Chu, Christopher 
H. Contag, Robert C. Robbins, Joseph C. Wu, Stanford Medical School, Stanford, CA
Background: Resident cardiac stem cells (CSCs) have been isolated and characterized 
in vitro and offers a novel method to regenerate damaged myocardium. Here we 
characterize and differentiate cardiac resident stem cell from L2G85 transgenic mice 
constitutively expressing both firefly (Fluc) and enhanced green fluorescence protein 
(eGFP) reporter gene. We use molecular imaging techniques to examine their survival in 
vivo, and determine the therapeutic efficacy for restoration of cardiac function following 
ischemic injury.
Methods and Results: CSCs were isolated from 6 to 12 week-old L2G85 transgenic 
mice (FVB background). FACS analysis showed expression of resident CSC markers 
(Sca1 and c-Kit) and mesenchymal stem cell markers (CD44, CD29, CD90, CD106). 
CSCs could differentiate into beating cardiomyocytes, endothelial cells, and adipocytes as 
confirmed by immunohistology, vascular-like channel formation on Matrigel, incorporation 
of DiI-labeled acetylated low-density lipoprotein (DiI-Ac-LDL), and staining with oil red. 
Afterwards, 5x105 CSCs or PBS (as control) was injected into the hearts of FVB mice 
(n=30) undergoing left anterior descending artery (LAD) ligation. Bioluminescence 
imaging showed longitudinal survival of transplanted CSCs for ~8 weeks. However, 
poor donor cell survival was observed with <0.5% of the transplanted CSCs still alive 
by week 8. Echocardiogram and positron emission tomography (PET) imaging with 
[18F]fluorodeoxyglucose ([18F]-FDG) demonstrated no significant difference in contractility 
and viability between the CSC and control group (P=0.46 & P=0.31, respectively). Finally, 
postmortem analysis confirmed transplanted cells integrated with host cardiomyocyte by 
eGFP and cardiac troponin T (cTnT) staining.
Conclusion: CSCs with mesenchymal features provide no long-term benefits to cardiac 
function in a mouse ischemic model of heart failure. Thus, the study raises caution on 
the clinical application of CSCs in patients with ischemic heart disease. Application of 
bioengineering methods or pro-survival growth factors, rather than direct cell injection 
alone, may by needed to achieve long-term engraftment in the future.
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Background: Reperfusion of the ischemic area is the culprit for myocardial injury. The 
major mediator of ischemic reperfusion (IR) injury is reactive oxygen species (ROS). 
We have recently showed that hydrogen (H2) gas selectively reduced cytotoxic ROS, 
especially hydroxyl radicals, and inhalation of H2 gas decreased cerebral infarction size 
after I/R injury (Ohsawa, Nat Med., 2007). Here, we asked whether inhalation of H2 gas is 
applicable for cardioprotection against I/R injury.
Methods: (1) The degree of protection was evaluated by measuring the infarct size after 
30 min LAD occlusion followed by 2 h of reperfusion in rats. Area at risk was assessed by 
blue dye and necrotic zone by TTC staining. (2) Cardiomyocytes were plated in culture 
medium containing either H2 (75%) + O2 (20%) + CO2 (5%) or Air (95%) + CO2 (5%). At 24 
hrs after the induction of ROS by a respiratory chain complex III inhibitor, antimycin A, live 
and dead cells were detected by calcein AM and ethidium homodimer, respectively. (3) To 
verify whether H2 protects against hydroxyl radicals, cardiomyocytes were treated with Cu2+ 
and ascorbate to induce hydroxyl radicals by Fenton reaction. The levels of hydroxyl radicals 
were assessed by the fluorescence signal emitted by hydroxyphenyl fluorescein.
Results: H2 dissolved in medium effectively reduced hydroxyl radicals in cardiomyocytes 
and improved cell viability. Inhalation of H2 gas (2%) prior to reperfusion also reduced the 
infarct size in vivo.
Conclusions: We proposed that inhalation of hydrogen gas is clinically applicable 
method to reduce myocardial I/R injury during reperfusion either by thrombolysis therapy, 
angioplasty, or surgical bypass grafting.
